Lv46
694 积分 2026-03-13 加入
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
24天前
已完结
NK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2
28天前
已完结
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
29天前
已完结
IL-7: Comprehensive review
29天前
已完结
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v
1个月前
已关闭
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
1个月前
已完结
Efficient generation of epitope-targeted antibodies with Germinal
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
3个月前
已完结
Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors
4个月前
已完结
皖公网安备34019202002308
